This work may not be copied, distributed, displayed, published, reproduced, transmitted, modified, posted, sold, licensed, or used for commercial purposes. By downloading this file, you are agreeing to the publisher’s Terms & Conditions.

Brainstorms

Independent Actions on Fear Circuits May Lead to Therapeutic Synergy for Anxiety When Combining Serotonergic and GABAergic Agents

Stephen M. Stahl

Published: October 1, 2002

Article Abstract

In last month’s BRAINSTORMS, we discussed the fact that benzodiazepines are still the leading treatments for anxiety disorders, despite their limitations and being relegated to second-line use in modern treatment guidelines. Benzodiazepines act upon GABAergic neurotransmission to enhance neuronal inhibition and are frequently used along with antidepressants that enhance serotonergic neurotransmission for the treatment of anxiety disorders today. Here we illustrate the neuroanatomical substrate of fear, showing that both GABA and serotonin have inhibitory actions on the output of the fear response from the amygdala.


Some JCP and PCC articles are available in PDF format only. Please click the PDF link at the top of this page to access the full text.

Related Articles

Volume: 63

Quick Links: Pain , Somatic Symptoms and Related Disorders

Sign-up to stay
up-to-date today!

SUBSCRIBE

Already registered? Sign In

Original Research

Sublingual Dexmedetomidine for the Treatment of Acute Agitation in Adults With Schizophrenia or Schizoaffective Disorder: A Randomized Placebo-Controlled Trial

This RCT determined whether a single dose of sublingual dexmedetomidine reduced acute agitation associated with schizophrenia or...

Read More...